Emerging data over the years has shown the role of GLP-1 receptor agonists, not only in terms of their initial role in managing diabetes and blood sugar but also the secondary benefit of sometimes massive amounts of weight loss. However, there hasn’t been a tremendous number of studies looking at the use of these agents in patients with HIV. Join Dr. Charles Turck as he dives into the data further with Dr. Darcy Wooten, Clinical Professor of Medicine and a Program Director for the University of California San Diego ID Fellowship Training Program in the Division of Infectious Diseases and Global Public Health.